Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Progressive Scleroderma Clear all
Completed Phase 1Phase 2 Interventional Results available

IL1-TRAP, Rilonacept, in Systemic Sclerosis

NCT01538719
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions
Rilonacept, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

NCT01808937
View directory record Official record
Conditions
Scleroderma, Localized, Morphea, Frontal Linear Scleroderma en Coup de Sabre, Scleroderma, Circumscribed, Scleroderma, Linear
Interventions
Morphea
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Completed No phase listed Observational

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Not applicable Interventional

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

NCT06675344
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Apollo Neuro Device, Sham device
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

NCT03798366
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Not listed No phase listed Observational

Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD

NCT04535245
View directory record Official record
Conditions
Scleroderma
Interventions
LCI testing
Diagnostic Test
Lead sponsor
National Jewish Health
Other
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

NCT00480753
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Jul 22, 2026, 10:10 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma

NCT02166229
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis
Interventions
Divalproex sodium
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Jul 22, 2026, 10:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Silicone-Associated Connective Tissue Diseases

NCT00001330
View directory record Official record
Conditions
Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

NCT02426229
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
dabigatran etexilate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801
View directory record Official record
Conditions
Scleroderma, Keloids, Other Fibrosing Conditions
Interventions
German manufactured UVA1 light emitting device
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Phase 1 Interventional

US Zamto-cel Autoimmune Diseases

NCT06708845
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Interventions
zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Taking Charge of Systemic Sclerosis

NCT02494401
View directory record Official record
Conditions
Scleroderma
Interventions
Internet-based self-management program, Scleroderma book
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

NCT00930683
View directory record Official record
Conditions
Scleroderma
Interventions
MEDI-546
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

NCT05462522
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RO7303509, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2225 in Healthy Participants (MK-2225-003)

NCT06643390
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
MK-2225, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Riociguat in Scleroderma Associated Digital Ulcers

NCT02915835
View directory record Official record
Conditions
Scleroderma, Digital Ulcers
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

NCT02283762
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 10:10 AM EDT